<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986439</url>
  </required_header>
  <id_info>
    <org_study_id>201101982</org_study_id>
    <nct_id>NCT01986439</nct_id>
  </id_info>
  <brief_title>The Contraceptive Choice Project</brief_title>
  <official_title>The Contraceptive Choice Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to remove barriers to obtaining contraceptive methods,
      including the most effective and expensive methods. The study seeks to remove the financial
      and knowledge barriers and promote the most effective contraceptive methods to reduce
      unintended pregnancy rates at the population level.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of contraceptive method chosen</measure>
    <time_frame>Baseline</time_frame>
    <description>Distribution of methods (%) chosen at baseline enrollment, by method and stratified by Long-Acting Reversible Contraception (LARC: intrauterine device and implant) and non-LARC (depotmedroxyprogesterone acetate (DMPA), oral contraceptive pill (OCP), vaginal ring, transdermal patch).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Method Continuation</measure>
    <time_frame>6-month, 12 month, 24-month, and 36-month</time_frame>
    <description>% of women using each method at 6, 12-, 24, and 36 months post-enrollment. Hazard rates via survival analysis comparing LARC and non-LARC methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Method Satisfaction</measure>
    <time_frame>12-month, 24-month, 36-month</time_frame>
    <description>% of women very or somewhat satisfied with method at 12, 24, and 36 months of use. Comparison of all methods and stratified by LARC and non-LARC methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Teen Pregnancy Rates</measure>
    <time_frame>1-year, 2-year, 3-year</time_frame>
    <description>Number of pregnancies per participants 15-19 years of age. We will calculate an annual rate for each year from 2007-2013 and also calculate a rate for the cohort followed for 1 year, 2 years, and 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat Abortion Rates</measure>
    <time_frame>1-year, 2-year, 3-year</time_frame>
    <description>Number of abortions among participants 15-44 with a history of abortion. We will calculate an annual rate for each year from 2007-2013 and also calculate a rate for the cohort followed for 1 year, 2 years, and 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexually transmitted infection rates</measure>
    <time_frame>Baseline and 12-months</time_frame>
    <description>Baseline prevalence rates (number positive divided by number tested) for chlamydia, gonorrhea, and trichomonas. 1-year incidence rates for the same infections among those who tested at 1-year.</description>
  </secondary_outcome>
  <enrollment type="Actual">9256</enrollment>
  <condition>Unintended Pregnancy</condition>
  <condition>Teen Births</condition>
  <condition>Abortion</condition>
  <condition>Contraception</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      vaginal swab specimens for chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis.
      Blood specimens for HIV and syphilis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women of reproductive age who reside in the St. Louis metropolitan region.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 14-45 years of age

          2. Primary residency in St. Louis City or County

          3. Does not desire pregnancy during the next 1 year

          4. Desires reversible contraception

          5. Sexually active with a man within the past 6 months or intend to have sex with a man
             in the next 6 months

          6. Is not currently using a contraceptive method, has begun using a new contraceptive
             method within the last 4 weeks, or is a current contraceptive method user who wants to
             switch to a NEW contraceptive method immediately

          7. Willing and able to undergo informed consent

          8. Willing to comply with study protocol and 2-year follow-up schedule

          9. Not currently pregnant, or meets one of the following criteria:

               1. Currently pregnant, undergoing medical or surgical termination of pregnancy, and
                  planning for post-abortion contraception

               2. Currently pregnant with an abnormal pregnancy (miscarriage or ectopic pregnancy),
                  undergoing medical or surgical management, and planning for post-pregnancy
                  contraception

               3. Currently pregnant, estimated gestational age of 36 weeks or greater, and
                  planning for post-partum contraception.

        Exclusion Criteria:

          1. History of hysterectomy or sterilization

          2. Current participation in another research study that would interfere with the conduct
             of this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey F Peipert, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.choiceproject.wustl.edu</url>
    <description>CHOICE Project Website</description>
  </link>
  <results_reference>
    <citation>Tepe M, Mestad R, Secura G, Allsworth JE, Madden T, Peipert JF. Association between tampon use and choosing the contraceptive vaginal ring. Obstet Gynecol. 2010 Apr;115(4):735-9. doi: 10.1097/AOG.0b013e3181d41c4a.</citation>
    <PMID>20308832</PMID>
  </results_reference>
  <results_reference>
    <citation>Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010 Aug;203(2):115.e1-7. doi: 10.1016/j.ajog.2010.04.017. Epub 2010 Jun 11.</citation>
    <PMID>20541171</PMID>
  </results_reference>
  <results_reference>
    <citation>Spain JE, Peipert JF, Madden T, Allsworth JE, Secura GM. The Contraceptive CHOICE Project: recruiting women at highest risk for unintended pregnancy and sexually transmitted infection. J Womens Health (Larchmt). 2010 Dec;19(12):2233-8. doi: 10.1089/jwh.2010.2146. Epub 2010 Sep 11.</citation>
    <PMID>20831439</PMID>
  </results_reference>
  <results_reference>
    <citation>Pittman ME, Secura GM, Allsworth JE, Homco JB, Madden T, Peipert JF. Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception. 2011 Apr;83(4):340-5. doi: 10.1016/j.contraception.2010.08.003. Epub 2010 Sep 17.</citation>
    <PMID>21397092</PMID>
  </results_reference>
  <results_reference>
    <citation>Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May;117(5):1105-13. doi: 10.1097/AOG.0b013e31821188ad.</citation>
    <PMID>21508749</PMID>
  </results_reference>
  <results_reference>
    <citation>Kittur ND, Secura GM, Peipert JF, Madden T, Finer LB, Allsworth JE. Comparison of contraceptive use between the Contraceptive CHOICE Project and state and national data. Contraception. 2011 May;83(5):479-85. doi: 10.1016/j.contraception.2010.10.001. Epub 2010 Nov 23.</citation>
    <PMID>21477693</PMID>
  </results_reference>
  <results_reference>
    <citation>Kossler K, Kuroki LM, Allsworth JE, Secura GM, Roehl KA, Peipert JF. Perceived racial, socioeconomic and gender discrimination and its impact on contraceptive choice. Contraception. 2011 Sep;84(3):273-9. doi: 10.1016/j.contraception.2011.01.004. Epub 2011 Feb 21.</citation>
    <PMID>21843693</PMID>
  </results_reference>
  <results_reference>
    <citation>Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception. 2011 Nov;84(5):493-8. doi: 10.1016/j.contraception.2011.03.001. Epub 2011 Apr 27.</citation>
    <PMID>22018123</PMID>
  </results_reference>
  <results_reference>
    <citation>Graseck AS, Secura GM, Allsworth JE, Madden T, Peipert JF. Home screening compared with clinic-based screening for sexually transmitted infections. Obstet Gynecol. 2010 Apr;115(4):745-52. doi: 10.1097/AOG.0b013e3181d4450d.</citation>
    <PMID>20308834</PMID>
  </results_reference>
  <results_reference>
    <citation>Graseck AS, Secura GM, Allsworth JE, Madden T, Peipert JF. Home compared with clinic-based screening for sexually transmitted infections: a randomized controlled trial. Obstet Gynecol. 2010 Dec;116(6):1311-8. doi: 10.1097/AOG.0b013e3181fae60d.</citation>
    <PMID>21099596</PMID>
  </results_reference>
  <results_reference>
    <citation>Shih SL, Kebodeaux CA, Secura GM, Allsworth JE, Madden T, Peipert JF. Baseline correlates of inconsistent and incorrect condom use among sexually active women in the contraceptive CHOICE Project. Sex Transm Dis. 2011 Nov;38(11):1012-9. doi: 10.1097/OLQ.0b013e318225f8c3.</citation>
    <PMID>21992976</PMID>
  </results_reference>
  <results_reference>
    <citation>Madden T, Secura GM, Allsworth JE, Peipert JF. Comparison of contraceptive method chosen by women with and without a recent history of induced abortion. Contraception. 2011 Dec;84(6):571-7. doi: 10.1016/j.contraception.2011.03.018. Epub 2011 May 4.</citation>
    <PMID>22078185</PMID>
  </results_reference>
  <results_reference>
    <citation>Madden T, Proehl S, Allsworth JE, Secura GM, Peipert JF. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol. 2012 Feb;206(2):129.e1-8. doi: 10.1016/j.ajog.2011.09.021. Epub 2011 Sep 24.</citation>
    <PMID>22055339</PMID>
  </results_reference>
  <results_reference>
    <citation>Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012 Mar;39(3):217-22. doi: 10.1097/OLQ.0b013e31823e68fe.</citation>
    <PMID>22337109</PMID>
  </results_reference>
  <results_reference>
    <citation>Skala SL, Secura GM, Peipert JF. Factors associated with screening for sexually transmitted infections. Am J Obstet Gynecol. 2012 Apr;206(4):324.e1-6. doi: 10.1016/j.ajog.2012.02.020. Epub 2012 Feb 28.</citation>
    <PMID>22464074</PMID>
  </results_reference>
  <results_reference>
    <citation>Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012 May 24;366(21):1998-2007. doi: 10.1056/NEJMoa1110855.</citation>
    <PMID>22621627</PMID>
  </results_reference>
  <results_reference>
    <citation>Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012 Dec;120(6):1291-7. doi: http://10.1097/AOG.0b013e318273eb56.</citation>
    <PMID>23168752</PMID>
  </results_reference>
  <results_reference>
    <citation>Secura GM, Desir FA, Mullersman JL, Madden T, Allsworth JE, Peipert JF. Predictors of male partner treatment for sexually transmitted infection. Sex Transm Dis. 2012 Oct;39(10):769-75.</citation>
    <PMID>23001263</PMID>
  </results_reference>
  <results_reference>
    <citation>McNicholas C, Peipert JF, Maddipati R, Madden T, Allsworth JE, Secura GM. Sexually transmitted infection prevalence in a population seeking no-cost contraception. Sex Transm Dis. 2013 Jul;40(7):546-51. doi: 10.1097/OLQ.0b013e31829529eb.</citation>
    <PMID>23965768</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenberg DL, Secura GM, Madden TE, Allsworth JE, Zhao Q, Peipert JF. Knowledge of contraceptive effectiveness. Am J Obstet Gynecol. 2012 Jun;206(6):479.e1-9. doi: 10.1016/j.ajog.2012.04.012. Epub 2012 Apr 6.</citation>
    <PMID>22521458</PMID>
  </results_reference>
  <results_reference>
    <citation>Madden T, Mullersman JL, Omvig KJ, Secura GM, Peipert JF. Structured contraceptive counseling provided by the Contraceptive CHOICE Project. Contraception. 2013 Aug;88(2):243-9. doi: 10.1016/j.contraception.2012.07.015. Epub 2012 Sep 5.</citation>
    <PMID>22959396</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012 Jul;120(1):21-6. doi: 10.1097/AOG.0b013e318259565a.</citation>
    <PMID>22678035</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012 Dec;120(6):1298-305. doi: http://10.1097/AOG.0b013e31827499bd.</citation>
    <PMID>23168753</PMID>
  </results_reference>
  <results_reference>
    <citation>Nault AM, Peipert JF, Zhao Q, Madden T, Secura GM. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate. Am J Obstet Gynecol. 2013 Jan;208(1):48.e1-8. doi: 10.1016/j.ajog.2012.10.876. Epub 2012 Oct 24.</citation>
    <PMID>23103344</PMID>
  </results_reference>
  <results_reference>
    <citation>Stuart JE, Secura GM, Zhao Q, Pittman ME, Peipert JF. Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol. 2013 Feb;121(2 Pt 1):330-6. doi: http://10.1097/AOG.0b013e31827e5898.</citation>
    <PMID>23344283</PMID>
  </results_reference>
  <results_reference>
    <citation>Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013 Oct;88(4):503-8. doi: 10.1016/j.contraception.2013.03.004. Epub 2013 Mar 18.</citation>
    <PMID>23582238</PMID>
  </results_reference>
  <results_reference>
    <citation>Oʼneil-Callahan M, Peipert JF, Zhao Q, Madden T, Secura G. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013 Nov;122(5):1083-91. doi: 10.1097/AOG.0b013e3182a91f45.</citation>
    <PMID>24104781</PMID>
  </results_reference>
  <results_reference>
    <citation>Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013 Dec;122(6):1214-21. doi: 10.1097/01.AOG.0000435452.86108.59.</citation>
    <PMID>24201685</PMID>
  </results_reference>
  <results_reference>
    <citation>McNicholas CP, Madden T, Zhao Q, Secura G, Allsworth JE, Peipert JF. Cervical lidocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol. 2012 Nov;207(5):384.e1-6. doi: 10.1016/j.ajog.2012.09.018. Epub 2012 Sep 20.</citation>
    <PMID>23107081</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jeffrey Peipert</investigator_full_name>
    <investigator_title>Robert J. Terry Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

